Bravecto tick protection efficacy was evaluated at 72 hours post-treatment for 12 weeks in a clinical field study. Results found that Bravecto has a ≥93% effectiveness for 12 weeks against
Ixodes scapularis (black-legged tick),
Dermacentor variabilis (American dog tick), and
Rhipicephalus sanguineus (brown dog tick) and ≥90% effectiveness for 8 weeks against
Amblyomma americanum (lone star tick).
1 It also found that Bravecto reduces exposure to ticks, which can carry tick-borne diseases.
